A Phase 1/2 Study to Evaluate ALN-KHK in Overweight to Obese Healthy Volunteers and Obese Patients With T2DM
Status:
Recruiting
Trial end date:
2025-07-01
Target enrollment:
Participant gender:
Summary
To evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of
single ascending doses of ALN-KHK and to evaluate the safety, tolerability, efficacy, PK and
PD of multiple doses of KHK.